<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:regn="http://regeneron.com/20210914">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_regn_regeneron.com_20210914 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20210914_20210914 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="regn-20210914.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-09-14to2021-09-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-09-14</xbrli:startDate>
        <xbrli:endDate>2021-09-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20210914__20210914_zUInVHd2DC89"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported): September 16, 2021 (<span id="xdx_903_edei--DocumentPeriodEndDate_c20210914__20210914_zjH5sryQn5mh"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 14, 2021</ix:nonNumeric></span>)</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90C_edei--EntityRegistrantName_c20210914__20210914_zGktcVj3sBHj"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20210914__20210914_zpY5AZNqseJ"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction of incorporation)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityFileNumber_c20210914__20210914_z9ONUWUu1IB"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20210914__20210914_z1Tnjx8Qfhzl"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td></tr>
<tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20210914__20210914_zlzCVxqs0dO4"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCityOrTown_c20210914__20210914_zwYj6hUkIlpi"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressStateOrProvince_c20210914__20210914_zS5tPZ4Q3DWc"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: bottom; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20210914__20210914_zRuE0PjHW305"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 8pt"><b>(Address of principal executive offices)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 8pt"><b>(Zip Code)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number, including area code: (<span id="xdx_903_edei--CityAreaCode_c20210914__20210914_zDn0ntcSO402"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_909_edei--LocalPhoneNumber_c20210914__20210914_zIRGxIEcG5w9"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_904_edei--WrittenCommunications_c20210914__20210914_ze5WsCrKbWtc"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_903_edei--SolicitingMaterial_c20210914__20210914_zt7z1wv6TZd8"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementTenderOffer_c20210914__20210914_ziPjPhLztgF"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementIssuerTenderOffer_c20210914__20210914_zsfec8MgAldf"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; font-size: 10pt; border-image: none; width: 33%; text-align: center; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 34%; text-align: center; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 33%; text-align: center; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_900_edei--Security12bTitle_c20210914__20210914_z8dxqbh6HI07"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:Security12bTitle">Common Stock &#8211; par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_905_edei--TradingSymbol_c20210914__20210914_zjzgTH3hpJse"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_90F_edei--SecurityExchangeName_c20210914__20210914_zl2xi2T7WFdf"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20210914__20210914_z1ezzB61HMcb"><ix:nonNumeric contextRef="From2021-09-14to2021-09-14" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01.&#160; Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">On
September&#160;14, 2021, Regeneron Pharmaceuticals,&#160;Inc. (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221; or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered
into a modified Statement of Work (the &#8220;<span style="text-decoration: underline">Amendment</span>&#8221;) under the supply agreement (the &#8220;<span style="text-decoration: underline">Supply Agreement</span>&#8221;
(previously filed as Exhibit&#160;10.1 to Regeneron&#8217;s Quarterly Report on Form&#160;10-Q for the quarterly period ended March&#160;31,
2021)) with the Army Contracting Command, New Jersey, an entity acting on behalf of the U.S. Department of Defense and the U.S. Department
of Health and Human Services (collectively, the &#8220;<span style="text-decoration: underline">U.S. Government</span>&#8221;), to supply to the U.S. Government an additional
1.4 million doses of REGEN-COV<sup>TM</sup> (</span><span style="background-color: white">casirivimab and imdevimab),</span> the Company&#8217;s
cocktail of two monoclonal antibodies that has received an Emergency Use Authorization from the U.S. Food and Drug Administration (the
&#8220;<span style="text-decoration: underline">FDA</span>&#8221;) for use in certain individuals in the United States. Pursuant to the Supply Agreement, as amended by the Amendment
(the &#8220;<span style="text-decoration: underline">Amended Supply Agreement</span>&#8221;), the U.S. Government is obligated to purchase all such filled and finished doses of
drug product delivered to vendor-managed inventory by January&#160;31, 2022. Regeneron is required to deliver at least 100,000 doses by
the end of each of September, October, November, and December&#160;2021, with the remaining doses to be delivered by January&#160;31,
2022, and to use commercially reasonable efforts to deliver doses early. In addition, the Amendment sets forth a good faith obligation
to deliver filled and finished doses of drug product based on a non-binding monthly schedule that, if met, would result in the delivery
of all doses by the end of 2021. The U.S. Government will acquire doses at the lowest therapeutic dose (other than a pediatric dose) authorized
or approved by the FDA prior to or on the date of delivery for a price of $2,100 per dose, resulting in payments to Regeneron of $2.940
billion in the aggregate based on the delivery of 1.4 million doses, and will be obligated to pay for partial deliveries. A number of
factors may impact available filled and finished supply, including manufacturing considerations. The Company is also obligated to distribute
the filled and finished drug product to patient care sites as directed by the U.S. Government.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Amended Supply Agreement contains terms and
conditions that are customary for U.S. Government agreements of this nature, including provisions giving the U.S. Government the right
to terminate the Amended Supply Agreement for convenience. If the Amended Supply Agreement is terminated for convenience prior to completion,
Regeneron is entitled to be paid certain termination costs, including the percentage of the contract price reflecting the percentage of
work performed plus certain reasonable charges resulting from termination.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing description of the Amended Supply Agreement is qualified in its entirety by reference to the full text of (i)&#160;the </span>Amendment,
a copy of which will be filed with the U.S. Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) as an exhibit to the Company&#8217;s
Quarterly Report on Form&#160;10-Q for the quarterly period ending September&#160;30, 2021; and (ii)&#160;the Supply Agreement, a copy
of which has been filed with the SEC as Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarterly
period ended March&#160;31, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><b><i>Note Regarding Forward-Looking
Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><i>This Current Report on Form&#160;8-K (this &#8220;Report&#8221;)
includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron
Pharmaceuticals,&#160;Inc. (&#8220;Regeneron&#8221; or the &#8220;Company&#8221;), and actual events or results may differ materially
from these forward-looking statements. Words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221;
&#8220;believe,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; variations of such words, and similar expressions are intended to identify
such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern,
and these risks and uncertainties include, among others, the ability of Regeneron and/or its collaborators, suppliers, or other third
parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron&#8217;s
products and product candidates (including REGEN-COV<sup>TM</sup> (casirivimab and imdevimab)) and the impact of the foregoing on Regeneron&#8217;s
ability to supply its products and product candidates, including its ability to supply doses of REGEN-COV under the terms of the amended
supply agreement with the U.S. government discussed in this Report (the &#8220;Amended Supply Agreement&#8221;); whether and to what extent
Regeneron will be able to supply doses of REGEN-COV under the Amended Supply Agreement; the amount of payments (if any) Regeneron may
receive pursuant to the Amended Supply Agreement; what the lowest therapeutic dose (other than a pediatric dose) authorized or approved
by the FDA will be at the time of delivery to the U.S. government under the Amended Supply Agreement; and whether the Amended Supply Agreement
is terminated by the U.S. government or otherwise prior to completion. A more complete description of these and other material risks can
be found in Regeneron&#8217;s filings with the U.S. Securities and Exchange Commission, including its Form&#160;10-K for the year ended
December&#160;31, 2020 and its Form&#160;10-Q for the quarterly period ended June&#160;30, 2021. Any forward-looking statements are made
based on management&#8217;s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made
by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without
limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 50%"><span style="font: 10pt Times New Roman, Times, Serif"><b>REGENERON PHARMACEUTICALS,&#160;INC.</b>&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="border-bottom: Black 1pt solid"><span style="font: 10pt Times New Roman, Times, Serif">/s/ Joseph J. LaRosa</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Joseph J. LaRosa</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President, General Counsel and Secretary</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: September&#160;16, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
